Last reviewed · How we verify
Dovonex® = calcipotriol
Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell proliferation and differentiation, reducing excessive keratinocyte growth.
Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell proliferation and differentiation, reducing excessive keratinocyte growth. Used for Plaque psoriasis, Psoriatic dermatitis.
At a glance
| Generic name | Dovonex® = calcipotriol |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Vitamin D3 analog |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriol acts as a selective vitamin D receptor agonist, promoting normal differentiation of keratinocytes and inhibiting their proliferation. This mechanism helps normalize the abnormal skin cell turnover characteristic of psoriasis and other hyperproliferative skin disorders. By modulating immune responses and reducing inflammatory cytokine production in the skin, it addresses both the cellular and immunological components of psoriatic plaques.
Approved indications
- Plaque psoriasis
- Psoriatic dermatitis
Common side effects
- Skin irritation at application site
- Burning or stinging sensation
- Erythema
- Hypercalcemia (with systemic absorption)
Key clinical trials
- Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis (PHASE4)
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
- Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis (PHASE3)
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris (PHASE1)
- Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dovonex® = calcipotriol CI brief — competitive landscape report
- Dovonex® = calcipotriol updates RSS · CI watch RSS
- LEO Pharma portfolio CI